The recent observation that CDK4/6 inhibitors, now widely employed to treat luminal-like BCs, not only restrain cancer cell proliferation but also favor antitumor immunity by inhibiting CD4+ Treg proliferation in preclinical models, may be important in this regard. Here, CD4 is linked to cancer.